Peptides DB
Research-centric peptide and protocol reference hub
Study 54 of 57Semaglutide literatureRenal failure · Observational2026

A study on risk factors for the progression from T2DM to end-stage renal disease based on Mendelian randomization and logistic regression analysis.

Elevated body mass index (BMI) is a causal risk factor for progression to end-stage renal disease in patients with type 2 diabetes mellitus, while higher hematocrit appears protective.

Read at Renal failureAdd to compare

Where it sits

this study against the rest of the semaglutide corpus
13
Preclinical
34
Observational · this one
2
Open-label
2
Randomised
6
Reviews

Summary and findings

This study investigated risk factors for progression from type 2 diabetes mellitus (T2DM) to end-stage renal disease (ESRD) using Mendelian randomization and logistic regression analysis. The T2DM GWAS dataset included 433,540 individuals, while a clinical cohort of 875 patients was analyzed, with 140 patients (16%) progressing to ESRD. Elevated body mass index (BMI) was identified as a causal risk factor, while higher hematocrit was protective.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
AUC of the logistic regression-based nomogram was 0.88 (95% CI: 0.85-0.91).n=8752026

Abstract

The authors’ words, as Renal failure supplied them

Using two-sample Mendelian randomization (MR) based on GWAS data from the IEU OpenGWAS project and a retrospective clinical cohort, this study investigated risk factors for progression from type 2 diabetes mellitus (T2DM) to end-stage renal disease (ESRD) and developed a predictive model. The T2DM GWAS dataset (ebi-a-GCST010118; 2020) included 433,540 individuals (77,418 cases and 356,122 controls). Multivariable MR, with inverse variance weighted as the primary method, was used to evaluate the causal effects of metabolic and hematologic traits on ESRD, while MR-Egger and Cochran's Q test assessed pleiotropy and heterogeneity. MR-PRESSO was used for outlier removal. In parallel, 875 patients with T2DM were analyzed using univariable and multivariable logistic regression; 140 patients (16%) progressed to ESRD. MR showed that elevated body mass index (BMI) was a causal risk factor, whereas higher hematocrit was protective. In the clinical cohort, BMI, diastolic blood pressure, and creatinine were identified as independent risk factors, while albumin and hematocrit were protective. Sensitivity analyses showed no significant horizontal pleiotropy, and all instrumental variables were sufficiently strong (F-statistics >10). A logistic regression-based nomogram achieved an AUC of 0.88 (95% CI: 0.85-0.91) with good calibration and outperformed XGBoost, Random Forest, and support vector machine models. Elevated BMI and lower hematocrit increase ESRD risk in T2DM, and the nomogram may support early risk stratification and precision intervention.

Background

This paper addresses the progression from type 2 diabetes mellitus (T2DM) to end-stage renal disease (ESRD), a significant health concern given the rising prevalence of diabetes. Prior research has identified various risk factors for ESRD, but the causal relationships remain unclear. This study aims to clarify these relationships using Mendelian randomization and logistic regression analysis, potentially informing risk stratification and intervention strategies.

Methods

The study utilized two-sample Mendelian randomization based on GWAS data from the IEU OpenGWAS project, analyzing 433,540 individuals. A retrospective clinical cohort of 875 patients with T2DM was also evaluated using univariable and multivariable logistic regression. The primary outcome was the progression to ESRD, with secondary outcomes including various metabolic and hematologic traits.

Results

In the clinical cohort, 140 patients (16%) progressed to ESRD. The analysis identified elevated body mass index (BMI) as a causal risk factor and higher hematocrit as protective. The logistic regression-based nomogram achieved an AUC of 0.88 (95% CI: 0.85-0.91), indicating good predictive performance.

Interpretation

The findings suggest that elevated BMI is a significant risk factor for ESRD in T2DM, aligning with previous literature that associates obesity with renal complications. However, the clinical significance of the identified risk factors may vary, and the relatively small sample size of the clinical cohort limits the generalizability of the results. The study's reliance on observational data may also introduce confounding factors that could affect the conclusions.

Key findings

  • 433,540 individuals in T2DM GWAS dataset, 77,418 cases and 356,122 controls.
  • 140 patients (16%) progressed to ESRD in the clinical cohort of 875.
  • AUC of the logistic regression-based nomogram was 0.88 (95% CI: 0.85-0.91).
  • F-statistics for all instrumental variables were greater than 10.

Limitations

  • retrospective data may introduce biases
  • small clinical cohort size (n=875)
  • observational methods limit causal inference
  • no long-term follow-up reported

Elsewhere in the Semaglutide corpus

DSemaglutide and Suicidality in Adults with Overweight or Obesity: A Bayesian Meta-Analysis of Randomized Trialsbiorxiv-preprint · Completed suicide: pooled OR 1.56 (95% CrI 0.55–4.67), P(OR > 1) = 80.6%, n=17,086 semaglutide vs 15,304 placebo.reviewBWeight loss with a lower dose compounded semaglutide and behavioral weight management program: A real-world matched retrospective cohort studybiorxiv-preprint · At 16 weeks, NMGP users lost 8.3% of their baseline weight.HumanBSide effects of lower dose compounded semaglutide paired with a behavioral management program: A real-world retrospective studybiorxiv-preprint · 34% lower relative odds of reporting GI side effects by week 16, p=0.001, n=2,481 per group.HumanBFeasibility and acceptability of an everyday patient-centered discussion model for primary care: An exploratory, single-center study in the VA primary care setting.PEC innovation · 2026 · n=23 · Mean SDM-Q-9 score was 90.9 out of 100.HumanBOral Health Outcomes with GLP1 Receptor Agonists Compared with Other Metabolic Interventionsbiorxiv-preprint · 2026 · 8.69% of GLP-1 users developed at least one newly documented oral-health condition.HumanCOral Semaglutide Preserves Islet of Langerhans Structure and Cellular Integrity in a Type 2 Diabetes Mellitus Rat Model: Histological, Immunohistochemical, and Biochemical Studybiorxiv-preprint · 2026 · P < 0.05 for islet size, β-cell mass, and insulin immunoreactivity.Animal